TMC
CDTX

Trellus Management Company’s Cidara Therapeutics CDTX Stock Holding History

Trellus Management Company’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,707
Closed -$249K – 67
2019
Q1 		$249K Hold
4,707
– – 0.47% 48
2018
Q4 		$221K Buy
4,707
+2,419
+106% +$173K 0.5% 42
2018
Q3 		$201K Hold
2,288
– – 0.29% 59
2018
Q2 		$238K Hold
2,288
– – 0.35% 51
2018
Q1 		$183K Sell
2,288
-760
-25% -$104K 0.33% 57
2017
Q4 		$415K Buy
3,048
+1,048
+52% +$159K 0.57% 48
2017
Q3 		$324K Sell
2,000
-250
-11% -$35.6K 0.44% 56
2017
Q2 		$338K Buy
+2,250
New +$311K 0.5% 53

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

Trellus Management Company's CDTX Position: Q2 2019 in Review

Trellus Management Company sold out of Cidara Therapeutics (CDTX) in Q2 2019, closing a stake of 4,707 shares — an estimated $249K sold.

Trellus Management Company first reported a position in CDTX in Q2 2017 and held it in 8 quarters. The position peaked at $415K in Q4 2017. 45 funds tracked by Wall St. Rank hold CDTX as of Q2 2019.

  • Trellus Management Company reported no remaining Cidara Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Trellus Management Company sold 4,707 Cidara Therapeutics shares in Q2 2019, an estimated $249K.
  • Trellus Management Company first reported a position in Cidara Therapeutics in Q2 2017 and held it in 8 quarters.
  • Trellus Management Company's Cidara Therapeutics position peaked at $415K in Q4 2017.
  • 45 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2019.

Based on Trellus Management Company's 13F filing for Q2 2019, filed 31 Jul 2019.